JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cuschieri, K S
Right arrow Articles by McGoogan, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cuschieri, K S
Right arrow Articles by McGoogan, E
Related Collections
Right arrow Microbiology
Right arrow Cancer: gynecological
Right arrow Molecular Medicine
Right arrow Sexually Transmitted Infections
Right arrow Screening
Journal of Clinical Pathology 2004;57:68-72
© 2004 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population

K S Cuschieri1, H A Cubie1, M W Whitley2, A L Seagar1, M J Arends3, C Moore1, G Gilkisson1, E McGoogan1

1 Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK
2 St Triduanas Medical Practice, 54 Moira Park, Edinburgh EH7 6RU, UK
3 University of Cambridge Pathology Department, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, UK

Correspondence to:
Dr K Cuschieri
Specialist Virology Centre, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK; kate.cuschieri{at}luht.scot.nhs.uk Aims: If human papillomavirus (HPV) testing is to be included within cervical screening programmes, the importance of multiple HPV infections in cervical neoplasia needs to be determined. This study investigated the diversity of multiple HPV types in a routine cervical screening population, and assessed associations with cervical neoplasia.

Methods: Overall HPV prevalence, type specific prevalence, and extent of multiple infection were assessed in residual material from 3444 liquid based cytology samples, using real time GP5+/GP6+ polymerase chain reaction for screening and linear array assay for genotyping. HPV status was studied in relation to age and concurrent cytological evidence of dyskaryosis.

Results: Twenty per cent of samples were HPV positive. HPV type diversity was broad, and multiple HPV infections occurred in half of the HPV positive samples. Younger women were significantly more likely to harbour multiple high risk HPV (HR-HPV) infections. Infections with multiple HR-HPV types were found in 3.4% of samples negative for neoplasia and in 33.3%, 41.8%, and 40.4% of samples with borderline, mild, or high grade dyskaryosis, respectively. Single HR-HPV infections were found in 4.9%, 38.6%, 45.0%, and 51.1% of negative, borderline, mild, or high grade dyskaryosis samples, respectively.

Conclusions: Multiple HR-HPV infections were most prevalent in young women. Multiple HR-HPV infections were not more frequent in high grade than in low grade cervical neoplasia, reflecting common sexual transmission of multiple HR-HPV. Prospective cohort studies linking sequential loss or gain of HPV types with cytological analysis are required to assess the impact of multiple HR-HPV infections on neoplastic progression.


Keywords: human papillomavirus; multiple infection; cervical neoplasia

Abbreviations: HIV, human immunodeficiency virus; HPV, human papillomavirus; HR, high risk; LBC, liquid based cytology; LA, linear array; LR, low risk; PCR, polymerase chain reaction




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
A. C. Rodriguez, M. Schiffman, R. Herrero, S. Wacholder, A. Hildesheim, P. E. Castle, D. Solomon, R. Burk, and On behalf of the Proyecto Epidemiologico Guanacast
Rapid Clearance of Human Papillomavirus and Implications for Clinical Focus on Persistent Infections
J Natl Cancer Inst, April 2, 2008; 100(7): 513 - 517.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. Naucler, W. Ryd, S. Tornberg, A. Strand, G. Wadell, K. Elfgren, T. Radberg, B. Strander, O. Forslund, B.-G. Hansson, et al.
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
N. Engl. J. Med., October 18, 2007; 357(16): 1589 - 1597.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
K. M. E. Gallagher and S. Man
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women
J. Gen. Virol., May 1, 2007; 88(5): 1470 - 1478.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
D. Saslow, P. E. Castle, J. T. Cox, D. D. Davey, M. H. Einstein, D. G. Ferris, S. J. Goldie, D. M. Harper, W. Kinney, A.-B. Moscicki, et al.
American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors
CA Cancer J Clin, January 1, 2007; 57(1): 7 - 28.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
J P A Baak, A-J Kruse, S J Robboy, E A M Janssen, B van Diermen, and I Skaland
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers
J. Clin. Pathol., October 1, 2006; 59(10): 1017 - 1028.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. Trottier, S. Mahmud, M. C. Costa, J. P. Sobrinho, E. Duarte-Franco, T. E. Rohan, A. Ferenczy, L. L. Villa, and E. L. Franco
Human papillomavirus infections with multiple types and risk of cervical neoplasia.
Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1274 - 1280.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
I. Kraus, T. Molden, R. Holm, A. K. Lie, F. Karlsen, G. B. Kristensen, and H. Skomedal
Presence of E6 and E7 mRNA from Human Papillomavirus Types 16, 18, 31, 33, and 45 in the Majority of Cervical Carcinomas
J. Clin. Microbiol., April 1, 2006; 44(4): 1310 - 1317.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
O N. Gill and C. M Lowndes
Data are still needed for HPV immunisation programme
BMJ, November 19, 2005; 331(7526): 1204 - 1204.
[Full Text]


Home page
J. Clin. Pathol.Home page
K S Cuschieri, H A Cubie, M W Whitley, G Gilkison, M J Arends, C Graham, and E McGoogan
Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study
J. Clin. Pathol., September 1, 2005; 58(9): 946 - 950.
[Abstract] [Full Text] [PDF]


Home page
Sex. Transm. Infect.Home page
Multiple high risk HPV infections and cervical screening
Sex. Transm. Inf., April 1, 2004; 80(2): 120 - 120.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.